Sakai F, Takeshima T, Tatsuoka Y, et al. - Researchers undertook a phase 2, double-blind, placebo-controlled study determining the efficacy and safety of erenumab for the prevention of episodic migraine in Japanese patients. They administered placebo or erenumab 28, 70, or 140 mg subcutaneously once per month for 6 months to 475 patients. They observed greater decreases in monthly migraine days for erenumab vs placebo. As per outcomes, monthly subcutaneous injections of erenumab 70 mg exhibited statistically significant and numerically maximal efficacy with a favorable safety profile. This implies that erenumab is a potential new therapy for migraine prevention in Japan.